Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study

Table 1 Patient baseline characteristics in FAS

Characteristics	Patients, n (%)
Age
Median age (range, years)	60 (35–74)
< 50 years	6 (14.0)
50–65 years	20 (46.5)
≥ 65 years	17 (39.5)
Sex
Female	23 (53.5)
Male	20 (46.5)
Race
Chinese	43 (100.0)
ECOG PS
0	6 (14.0)
1	37 (86.0)
EGFR-sensitive mutation type
Exon 19 deletion	28 (65.1)
L858R	13 (30.2)
G719X^a and S768I mutations	1 (2.3)
L861Q	1 (2.3)
CNS metastases
Yes	12 (27.9)
No	31 (72.1)
Prior anti-cancer therapy
Surgery	1 (2.3)
Chemotherapy	0
Radiotherapy	2 (4.7)
Other ^b	1 (2.3)

Abbreviations: CNS Central nervous system, ECOG Eastern Cooperative Oncology Group, PS Performance status, FAS Full analysis set, EGFR Epidermal growth factor receptor
^aThe Cobas® EGFR Mutation Test, Version 2, Roche Diagnostics, South Branchburg, NJ, USA, was used for EGFR mutations detection, which was not able to further confirm this patient’s specific G719X type
^bOne patient received prior anticancer therapy with traditional Chinese medicine

ISSN: 1741-7015